31 Oct 2013, BioSpectrum Bureau , BioSpectrum
Singapore: AB Sciex, a global firm in analytical technologies, has opened a new R&D center in Singapore.
The facility is an extension of the company's $10 million global operations in Marsiling where the life science industry's leading analytical instruments, including the AB SCIEX 6500 series and TripleTOF series, are manufactured.
Focused on product development, the new AB Sciex R&D center is designed to enhance product quality and deliver incremental cost savings while reducing delivery time to AB SCIEX customers. Since a pre-opening roll-out phase started a year ago, the center has helped the company realize $1.6 million in savings.
As a global leader in scientific technologies for biological and chemical analysis, AB Sciex spends close to 10 percent of its annual revenues on R&D, which is a driving force for the company's continued innovation in LC/MS/MS (liquid chromatography/tandem mass spectrometry).
The company has also invested in an application support and training facility in the Biopolis, which is Singapore's state-of-the-art biomedical research hub housing a community of public and private researchers.
"Our significant investments in R&D, manufacturing and personnel reaffirm our commitment to Singapore as a hub for AB SCIEX global operations," said Mr Rainer Blair, president, AB Sciex. "As a trusted partner with scientists all over the world, we will continue to drive new innovation and push the limits of analytical science."
"We are excited about the opening of AB Sciex's R&D center in Singapore, its first R&D center outside North America. The center will design and develop new instruments from Singapore for global markets. This is an excellent example of how leading life science tools companies such as AB Sciex are looking to Singapore as an integrated home in Asia for complex instrument manufacturing, headquarter functions as well as R&D to support their future growth," said Ms Thien Kwee Eng, assistant MD, Singapore Economic Development Board.